Xcell Biosciences, Inc. (Xcellbio), a company specializing in platform technology for cell and gene therapy applications, has recently announced a collaboration with ElevateBio, LLC (ElevateBio). The partnership aims to explore innovative approaches to enhance the therapeutic potency of cell and gene therapies. ElevateBio is set to become the first member of Xcellbio’s beta program for its newly introduced AVATAR Foundry™ device. Additionally, Michael Paglia, Chief Technology Officer at ElevateBio’s BaseCamp®, has joined Xcellbio’s Scientific Advisory Board.

ElevateBio is a technology-driven company focused on commercializing enabling technologies, manufacturing capabilities, and industry-leading expertise through partnerships to expedite the development of genetic medicines. The company integrates its BaseCamp process development and current Good Manufacturing Practice (cGMP) manufacturing business with a technology stack, including gene editing, cell engineering technologies, and viral and non-viral delivery.

Mr. Paglia expressed his enthusiasm, stating, "At BaseCamp, we collaborate with industry partners to design the best process for their product and recognize the importance of emerging technologies that will revolutionize how cell and gene therapies are manufactured. I am excited to join the Xcellbio advisory board and look forward to collaborating with Brian and the team at BaseCamp."

As part of the collaboration, ElevateBio BaseCamp scientists will have access to Xcellbio’s AVATAR™ incubator system for cell therapy research and development, along with two new platforms: the AVATAR Ai™ system for measuring the potency of cell therapies and the AVATAR Foundry system for cGMP cell therapy manufacturing. The AVATAR and AVATAR Foundry systems aim to metabolically reprogram therapeutic cells to enhance their potency and persistence in the tumor microenvironment (TME), while the AVATAR Ai provides real-time analysis of tumor cytotoxicity under TME conditions. These collaborative efforts aim to streamline manufacturing protocols for cell and gene therapies.

Brian Feth, co-founder, and CEO at Xcellbio, expressed excitement about the collaboration, saying, "We are thrilled to collaborate with ElevateBio, a true leader in the cell and gene therapy field, and we look forward to making a collective impact in how these important treatments are utilized to improve healthcare. We also welcome Mike to our advisory board and are eager for his contributions to our own R&D programs in that capacity."

 

Source: businesswire.com

Report Abuse